Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-Mediated C-H functionalization

ACS Chemical Biology

Volumn 9, Issue 1, 2014, Pages 164-173

  Kolev, Joshua N ^a   O'Dwyer, Kristen M ^b   Jordan, Craig T ^b,c   Fasan, Rudi ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYTOCHROME P450; PARTHENOLIDE; CARBON; HYDROGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON HYDROGEN BOND; CATALYST; CHEMICAL BOND; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYDROXYLATION; ISOMERIZATION; LEUKEMIA CELL; MICROBIAL METABOLISM; MULTIPLE LINEAR REGRESSION ANALYSIS; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE; OXIDATION; PRIORITY JOURNAL; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY; ACUTE MYELOBLASTIC LEUKEMIA; CYTOTOXICITY; DRUG HYDROXYLATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME SYNTHESIS; HYDROGEN BOND; PREDICTION; REGIOSELECTIVITY; STEM CELL; STEREOSELECTIVITY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOCATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, MOLECULAR; OXIDATION-REDUCTION; SESQUITERPENES; TUMOR CELLS, CULTURED;

EID: 84899641647     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400626     Document Type: Article

References (63)

1. Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N. A., and Darwiche, N. (2010) What made sesquiterpene lactones reach cancer clinical trials? Drug Discovery Today 15, 668-678.
2. Janecka, A., Wyrebska, A., Gach, K., Fichna, J., and Janecki, T. (2012) Natural and synthetic α-methylenelactones and α-methylenelactams with anticancer potential. Drug Discovery Today 17, 561-572.
3. Guzman, M. L., and Jordan, C. T. (2005) Feverfew: Weeding out the root of leukaemia. Expert Opin. Biol. Ther. 5, 1147-1152. (Pubitemid 41243350)
4. Kreuger, M. R., Grootjans, S., Biavatti, M. W., Vandenabeele, P., and DHerde, K. (2012) Sesquiterpene lactones as drugs with multiple targets in cancer treatment: Focus on parthenolide. Anticancer Drugs 23, 883-896.
5. Guzman, M. L., Rossi, R. M., Karnischky, L., Li, X. J., Peterson, D. R., Howard, D. S., and Jordan, C. T. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163-4169. (Pubitemid 40720758)
6. Guzman, M. L., Karnischky, L., Li, X. J., Neering, S. J., Rossi, R. M., and Jordan, C. T. (2004) Selective induction of apoptosis in acute myelogenous leukemia stem cells by the novel agent parthenolide. Blood 104, 697a-697
7. Guzman, M. L., Rossi, R. M., Li, X. J., Corbett, C., Hassane, D. C., Bushnell, T., Carroll, M., Sullivan, E., Neelakantan, S., Crooks, P. A., and Jordan, C. T. (2006) A novel orally available parthenolide analog selectively eradicates AML stem and progenitor cells. Blood 108, 74a-74
8. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Cacerescortes, J., Minden, M., Paterson, B., Caligiuri, M. A., and Dick, J. E. (1994) A cell initiating human acute myeloid-leukemia after transplantation into SCID mice. Nature 367, 645-648. (Pubitemid 24067706)
9. Bonnet, D., and Dick, J. E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 3, 730-737. (Pubitemid 27298715)
10. van Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., and Schuurhuis, G. J. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520-6527. (Pubitemid 41338990)
11. Graham, S. M., Jorgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., and Holyoake, T. L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325.
12. Costello, R. T., Mallet, F., Gaugler, B., Sainty, D., Arnoulet, C., Gastaut, J. A., and Olive, D. (2000) Human acute myeloid leukemia CD34+/CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 60, 4403-4411. (Pubitemid 32103618)
13. Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., and Jordan, C. T. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. U.S.A. 99, 16220-16225. (Pubitemid 35462776)
14. Sweeney, C. J., Mehrotra, S., Sadaria, M. R., Kumar, S., Shortle, N. H., Roman, Y., Sheridan, C., Campbell, R. A., Murry, D. J., Badve, S., and Nakshatri, H. (2005) The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol. Cancer Ther. 4, 1004-1012. (Pubitemid 40909083)
15. Zhou, J., Zhang, H., Gu, P., Bai, J., Margolick, J. B., and Zhang, Y. (2008) NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat. 111, 419-427.
16. Zhang, D., Qiu, L., Jin, X., Guo, Z., and Guo, C. (2009) Nuclear factor-κB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol. Cancer Res. 7, 1139-1149.
17. Kawasaki, B. T., Hurt, E. M., Kalathur, M., Duhagon, M. A., Milner, J. A., Kim, Y. S., and Farrar, W. L. (2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 69, 827-837.
18. Wen, J., You, K. R., Lee, S. Y., Song, C. H., and Kim, D. G. (2002) Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. 277, 38954-38964. (Pubitemid 35154761)
19. Park, J. H., Liu, L., Kim, I. H., Kim, J. H., You, K. R., and Kim, D. G. (2005) Identification of the genes involved in enhanced fenretinideinduced apoptosis by parthenolide in human hepatoma cells. Cancer Res. 65, 2804-2814. (Pubitemid 40490083)
20. Zanotto-Filho, A., Braganhol, E., Schroder, R., de Souza, L. H., Dalmolin, R. J., Pasquali, M. A., Gelain, D. P., Battastini, A. M., and Moreira, J. C. (2011) NFκB inhibitors induce cell death in glioblastomas. Biochem. Pharmacol. 81, 412-424.
21. Yip-Schneider, M. T., Nakshatri, H., Sweeney, C. J., Marshall, M. S., Wiebke, E. A., and Schmidt, C. M. (2005) Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Mol. Cancer Ther. 4, 587-594. (Pubitemid 40601840)
22. Zuch, D., Giang, A. H., Shapovalov, Y., Schwarz, E., Rosier, R., OKeefe, R., and Eliseev, R. A. (2012) Targeting radioresistant osteosarcoma cells with parthenolide. J. Cell Biochem. 113, 1282-1291.
23. Garcia-Pineres, A. J., Castro, V., Mora, G., Schmidt, T. J., Strunck, E., Pahl, H. L., and Merfort, I. (2001) Cysteine 38 in p65/ NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 276, 39713-39720.
24. Garcia-Pineres, A. J., Lindenmeyer, M. T., and Merfort, I. (2004) Role of cysteine residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci. 75, 841-856. (Pubitemid 38737421)
25. Hehner, S. P., Heinrich, M., Bork, P. M., Vogt, M., Ratter, F., Lehmann, V., Schulze-Osthoff, K., Droge, W., and Schmitz, M. L. (1998) Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of I κ B-α and I κ B-β. J. Biol. Chem. 273, 1288-1297. (Pubitemid 28133643)
26. Gopal, Y. N., Chanchorn, E., and Van Dyke, M. W. (2009) Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 8, 552-562.
27. Zhang, S., Ong, C. N., and Shen, H. M. (2004) Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett. 211, 175-188. (Pubitemid 38824631)
28. Skalska, J., Brookes, P. S., Nadtochiy, S. M., Hilchey, S. P., Jordan, C. T., Guzman, M. L., Maggirwar, S. B., Briehl, M. M., and Bernstein, S. H. (2009) Modulation of cell surface protein free thiols: A potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One 4, e8115.
29. Wang, W., Adachi, M., Kawamura, R., Sakamoto, H., Hayashi, T., Ishida, T., Imai, K., and Shinomura, Y. (2006) Parthenolideinduced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 11, 2225-2235. (Pubitemid 44885398)
30. Liu, Z., Liu, S., Xie, Z., Pavlovicz, R. E., Wu, J., Chen, P., Aimiuwu, J., Pang, J., Bhasin, D., Neviani, P., Fuchs, J. R., Plass, C., Li, P. K., Li, C., Huang, T. H., Wu, L. C., Rush, L., Wang, H., Perrotti, D., Marcucci, G., and Chan, K. K. (2009) Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J. Pharmacol. Exp. Ther. 329, 505-514.
31. Gopal, Y. N., Arora, T. S., and Van Dyke, M. W. (2007) Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem. Biol. 14, 813-823. (Pubitemid 47081425)
32. Neelakantan, S., Nasim, S., Guzman, M. L., Jordan, C. T., and Crooks, P. A. (2009) Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1). Bioorg. Med. Chem. Lett. 19, 4346-4349.
33. Nasim, S., and Crooks, P. A. (2008) Antileukemic activity of aminoparthenolide analogs. Bioorg. Med. Chem. Lett. 18, 3870-3873.
34. Hwang, D. R., Chang, C. W., Lien, T. W., Chen, W. C., Tan, U. K., Hsu, J. T. A., and Hsieh, H. P. (2006) Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorgan. Med. Chem. 14, 83-91. (Pubitemid 41635471)
35. Han, C., Barrios, F. J., Riofski, M. V., and Colby, D. A. (2009) Semisynthetic derivatives of sesquiterpene lactones by palladiumcatalyzed arylation of the α-methylene-lactone substructure. J. Org. Chem. 74, 7176-7179.
36. Woods, J. R., Mo, H., Bieberich, A. A., Alavanja, T., and Colby, D. A. (2011) Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as (19)f NMR probes in deuterium-free environments. J. Med. Chem. 54, 7934-7941.
37. Kwok, B. H., Koh, B., Ndubuisi, M. I., Elofsson, M., and Crews, C. M. (2001) The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem. Biol. 8, 759-766. (Pubitemid 32752455)
38. Zhang, K., El Damaty, S., and Fasan, R. (2011) P450 fingerprinting method for rapid discovery of terpene hydroxylating P450 catalysts with diversified regioselectivity. J. Am. Chem. Soc. 133, 3242-3245.
39. Zhang, K., Shafer, B. M., Demars, M. D., 2nd, Stern, H. A., and Fasan, R. (2012) Controlled oxidation of remote sp3 C-H bonds in artemisinin via P450 catalysts with fine-tuned regio-And stereoselectivity. J. Am. Chem. Soc. 134, 18695-18704.
40. Glieder, A., Farinas, E. T., and Arnold, F. H. (2002) Laboratory evolution of a soluble, self-sufficient, highly active alkane hydroxylase. Nat. Biotechnol. 20, 1135-1139. (Pubitemid 35285443)
41. Fasan, R., Chen, M. M., Crook, N. C., and Arnold, F. H. (2007) Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting native-like catalytic properties. Angew. Chem., Int. Ed. 46, 8414-8418. (Pubitemid 350114951)
42. Rentmeister, A., Arnold, F. H., and Fasan, R. (2009) Chemoenzymatic fluorination of unactivated organic compounds. Nat. Chem. Biol. 5, 26-28.
43. Whitehouse, C. J., Bell, S. G., Tufton, H. G., Kenny, R. J., Ogilvie, L. C., and Wong, L. L. (2008) Evolved CYP102A1 (P450BM3) variants oxidize a range of non-natural substrates and offer new selectivity options. Chem. Commun., 966-968. (Pubitemid 351281049)
44. Li, S., Chaulagain, M. R., Knauff, A. R., Podust, L. M., Montgomery, J., and Sherman, D. H. (2009) Selective oxidation of carbolide C-H bonds by an engineered macrolide P450 monooxygenase. Proc. Natl. Acad. Sci. U.S.A. 106, 18463-18468.
45. Weber, E., Seifert, A., Antonovici, M., Geinitz, C., Pleiss, J., and Urlacher, V. B. (2011) Screening of a minimal enriched P450 BM3 mutant library for hydroxylation of cyclic and acyclic alkanes. Chem. Commun. 47, 944-946.
46. Robin, A., Roberts, G. A., Kisch, J., Sabbadin, F., Grogan, G., Bruce, N., Turner, N. J., and Flitsch, S. L. (2009) Engineering and improvement of the efficiency of a chimeric [P450cam-RhFRed reductase domain] enzyme. Chem. Commun., 2478-2480.
47. Bordeaux, M., Galarneau, A., Fajula, F., and Drone, J. (2011) A regioselective biocatalyst for alkane activation under mild conditions. Angew. Chem., Int. Ed. 50, 2075-2079.
48. Rea, V., Kolkman, A. J., Vottero, E., Stronks, E. J., Ampt, K. A., Honing, M., Vermeulen, N. P., Wijmenga, S. S., and Commandeur, J. N. (2012) Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies. Biochemistry 51, 750-760.
49. Fasan, R. (2012) Tuning P450 enzymes as oxidation catalysts. ACS Catal. 2, 647-666.
50. Narhi, L. O., and Fulco, A. J. (1987) Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J. Biol. Chem. 262, 6683-6690.
51. Bloszyk, E., Budesinsky, M., Daniewski, W. M., Peskova, E., Drozdz, B., and Holub, M. (1990) Sesquiterpene lactones of Inula aschersoniana. Collect. Czech. Chem. Commun. 55, 1562-1567.
52. Abdel Sattar, E., Galal, A. M., and Mossa, G. S. (1996) Antitumor germacranolides from Anvillea garcinii. J. Nat. Prod. 59, 403-405. (Pubitemid 26139716)
53. Galal, A. M., Ibrahim, A. R. S., Mossa, J. S., and El-Feraly, F. S. (1999) Microbial transformation of parthenolide. Phytochemistry 51, 761-765. (Pubitemid 29289196)
54. Nasim, S., Pei, S., Hagen, F. K., Jordan, C. T., and Crooks, P. A. (2011) Melampomagnolide B: A new antileukemic sesquiterpene. Bioorg. Med. Chem. 19, 1515-1519.
55. Gonzalez, A. G., Galindo, A., Afonso, M. M., Mansilla, H., and Lopez, M. (1988) The biomimetic cyclization of melampomagnolide-B. Tetrahedron 44, 4585-4589.
56. Cuissart, B., Touffet, F., Cremilleux, B., Bureau, R., and Rault, S. (2002) The maximum common substructure as a molecular depiction in a supervised classification context: Experiments in quantitative structure/biodegradability relationships. J. Chem. Inf. Comput. Sci. 42, 1043-1052. (Pubitemid 35360287)
57. Cao, Y., Jiang, T., and Girke, T. (2008) A maximum common substructure-based algorithm for searching and predicting drug-like compounds. Bioinformatics 24, 366-374.
58. Rahman, S. A., Bashton, M., Holliday, G. L., Schrader, R., and Thornton, J. M. (2009) Small molecule subgraph detector (SMSD) toolkit. J. Cheminform. 1, 1-13.
59. Sevrioukova, I. F., Li, H., Zhang, H., Peterson, J. A., and Poulos, T. L. (1999) Structure of a cytochrome P450-redox partner electrontransfer complex. Proc. Natl. Acad. Sci. U.S.A. 96, 1863-1868. (Pubitemid 29117833)
60. Oliver, C. F., Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L. Y., and Roberts, G. C. (1997) A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation. Biochemistry 36, 1567-1572. (Pubitemid 27086252)
61. McLachlan, M. J., Johannes, T. W., and Zhao, H. (2008) Further improvement of phosphite dehydrogenase thermostability by saturation mutagenesis. Biotechnol. Bioeng. 99, 268-274. (Pubitemid 351158275)
62. Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., and Jordan, C. T. (2001) Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307.
63. Quick, A., and Rogers, D. (1976) Crystal and molecularstructure of parthenolide [4,5-epoxygermacra-1(10),11(13)-dien-12,6-olactone]. J. Chem. Soc., Perkin Trans. 2, 465-469.